Vystar Corp Stock Price, News & Analysis

Vystar (OTCQB: VYST) acquired 100% of Fluid Energy Conversion (FEC) assets, including the patented Hughes Reactor, and says a water filtration enhancement device is in final prototype testing to improve dialysis efficiency. Vystar expects FEC tech to reduce RxAir purifier size and cost, boost pathogen kill rates, and enable eco-friendly product initiatives across water, metering, and medical uses.

The company cites an estimated 1.7 billion gallons saved for one dialysis company and anticipates completing final testing in the current quarter.

Vystar (OTCQB: VYST) submitted a binding Letter of Intent dated Dec 4, 2025 to acquire a minority equity stake in GoPaid.com LLC and a percentage of GoPaid’s proprietary cryptocurrency or the lesser of a $10 million valuation.

The initial purchase price is 1,000 shares of Series C preferred common stock, with options to acquire up to an additional 10% equity and 3% cryptocurrency/b over two years, exercisable semi-annually. Target closing is on or before . Vystar committed to help raise $250,000 and to partner with Capital R3alm to launch R3alm Oracle and a Q2 2026 white-label R3alm Collectibles marketplace.

Vystar (OTCQB: VYST) announced a court victory dated Dec. 22, 2025 after four years of litigation against EMA Financial that resulted in dismissal of EMA’s suit seeking damages “in excess of $4,226,187.”

The U.S. Court of Appeals for the Second Circuit denied EMA’s appeal and the court awarded Vystar $497,439.58 in legal fees and costs. Vystar thanked its litigation and corporate counsel and named outside accountants who supported the case.

Vystar (OTCQB: VYST) announced that Internet and Incubator Stock Review initiated coverage on October 24, 2025, citing Vystar’s portfolio of four start-ups and development support for management, structuring and marketing.

Highlights include Vytex latex alternatives for medical and consumer uses, FDA-cleared RxAir 400 air purifier covering up to 800 sq ft, energy technologies at FEC, and a planned GoPaid.com tokenization portal with a full launch expected in Q4 2025 and a BETA imminent. The research firm emphasized tokenization’s potential to expand access to the collectibles and fine art market.

Vystar (OTCQB: VYST) announced on October 17, 2025 that the Vytex® Cloud Bed-in-a-Box collection is available for sale exclusively at www.vytex.com.

The line features 100% natural deproteinized Vytex latex in three support levels (firm, plush, super plush), six sizes, a 9-inch thickness, a quilted organic cotton over Joma wool cover, a free topper, and optional pillows and toppers. Product claims include 99.8% protein removal, a 90% stronger bond for durability, full biodegradability, and an expected useful life of 20+ years. Bed-in-a-Box industry sales are noted at nearly 35% of mattress sales.

Vystar Corporation (OTCQB: VYST) announced the relaunch of its Vytex® Cloud Bed-in-a-Box mattress collection, targeting the rapidly growing $30 billion mattress industry. The product line features 100% natural latex mattresses available in three support levels and six sizes, with bed-in-a-box sales now representing nearly 30% of all mattress sales.

The 9-inch thick mattresses will be available from October 1st, 2025, featuring a quilted organic cotton over Joma™ wool cover. Key product features include 20+ years of durability, natural antimicrobial properties, and Vystar's multi-patented deproteinization technology that removes 99.8% of allergy-causing proteins. The company offers a 100-day free trial and a 10-year warranty against manufacturing defects.

Vystar Corporation (OTCQB: VYST) has introduced an enhanced version of its RxAir400 UV-C light air purification system with new features. The key innovation is the Extended Life 18,000 Hour RxAir400 UV-C Pro bulb replacement cartridge, doubling the lifespan of the standard 9,000-hour cartridge.

The company has also added an ergonomic integrated handle and wall mount bracket options for improved portability. The RxAir400, a smaller version of the FDA-certified Class II medical device Rx3000, is proven to inactivate >99.9% of airborne pathogens including coronavirus strains. With 25,000 RxAir units operating worldwide, the market demands approximately 40,000 cartridge changes annually. The new extended life cartridge is priced at $375, offering cost savings compared to the standard $199 cartridge.

Vystar Corporation (OTCQB: VYST) has introduced a breakthrough ultrasoft 55 density Vytex natural latex mattress topper to its product lineup. The company has developed proprietary molding technology that enables the production of large-format ultrasoft latex sheets while maintaining consistent density, previously only achievable in smaller items like pillows.

The new topper features a 55 density rating (14 ILD equivalent) and is available in various sizes up to California king with 1-3 inch thickness options. Key features include enhanced durability, pressure point relief, natural anti-microbial properties, and virtually allergen-free composition with 99.8% of proteins removed. The product is environmentally friendly, being sustainably produced and biodegradable.

Vystar (OTCQB: VYST) has secured a significant legal victory as the Second Circuit Court affirmed the dismissal of a $4.2 million claim by EMA Financial LLC related to a toxic convertible note issue. The original November 2024 district court ruling not only dismissed EMA's complaint but also awarded Vystar legal fees.

While the Second Circuit's July 17, 2025 decision upholds the dismissal, it did not reverse the district court's denial of Vystar's counterclaims. The case now returns to district court for determination of legal fees, with Vystar having accrued approximately $1 million from 2018 to date. This marks a historic victory as the first successful defense by a micro-cap issuer against EMA Financial's breach of contract claims on convertible notes.